PhAST announces initial closing of $10.6M in Series A funding

Cambridge, Massachusetts⁠—January 18, 2022—PhAST Corp. (PhAST), a healthcare technology company developing artificial intelligence-powered diagnostic technology to combat antibiotic resistance, announced today that it has raised $10.6M in Series A funding. SV investment led the round, with significant participation from strategic investors LabCorp (Laboratory Corporation of America Holdings) and Naver Cloud (Naver Cloud Corporation) alongside notable angel investors. The company will use the funds to support clinical studies and accelerate product development toward a commercial launch. PhAST is headquartered in Cambridge, MA, with two international offices in Zurich, Switzerland and Seoul, South Korea. The company collaborates with leading healthcare institutions such as Brigham and Women’s Hospital, the Infectious Disease Institute at Harvard Medical School, and Seoul National University Hospital in South Korea.

Dr. John Thomas Sauls joins as Head of Bioengineering – August 2020

With a PhD from UCSD and in-depth expertise on microbial imaging, microscopy, microfluidics, and data science, Dr. John Thomas (JT) Sauls joins PhAST as Head of Bioengineering to commercialize PhAST’s AI-enabled technology.

PhAST expands to Asia – August 2020

PhAST has opened an office in Asia, its second international office after Zurich. Through a clinical research collaboration with one of South Korea’s best hospitals (Seoul National University Hospital), PhAST will accelerate its AI training and clinical validation effort.


Yongkyu Kim joins as Head of Asia Operations – July 2020

Bringing over ten years of industry experience at Samsung, Yongkyu Kim joins PhAST as Head of Asia operations to lead the newly opened Seoul office and expand PhAST’s international presence in the region.

PhAST graduates the Endless Frontier Labs program at New York University’s Stern School of Business – May 2020

PhAST has graduated the EFL program, successfully meeting all 8-week goals established by the program mentors and advisors. The company is grateful for the opportunity and meaningful relations built during the program.

PhAST invited to present at AMR Conference in Basel – March 2020

PhAST was invited to present in the “Diagnostics in clinical trial settings” session of the 4th AMR Conference in Basel, Switzerland [delayed to August 2020 due to COVID]

PhAST invited to present at the Presidential Advisory Council – February 2020

PhAST was invited to present its unique rapid antimicrobial diagnostic technology at the Presidential Advisory Council (PACCARB) meeting, Department of Human and Health Services, in Washington DC.

William Shubert joins as Head of Software Engineering – January 2020

Bringing 30 years of experience as a software engineer, including at Amazon, Intel, and several startups, William Shubert joins PhAST as Head of Software Engineering. Bill will lead the software engineering team in developing a software engine that matches the unique speed of PhAST’s antimicrobial diagnostic technology.

Dr. Vicente Fernandez joins as Director of Data Science – November 2019

Dr. Vicente Fernandez, a world expert in computer vision applied to microbiology, joins PhAST as Director of Data Science. Vicente holds degrees from Caltech and MIT and will guide PhAST’s data team to develop the ‘brains’ of its uniquely rapid antibiotic susceptibility testing technology.

PhAST selected to participate in Endless Frontier Labs at New York University’s Stern School of Business – September 2019

Endless Frontier Labs is a 9-month accelerator program for science- and technology-based startups, providing deep connections to the thriving New York startup ecosystem and investors.

PhAST receives SBIR Phase I award from NIH – August 2019

PhAST received a competitive Small Business Innovation Research (SBIR) award from NIH/NIAID to further its antibiotic susceptibility platform for rapid testing of pathogens directly from patient samples.

PhAST receives Massachusetts state government award – June 2019

PhAST was awarded a Massachusetts Life Sciences Center Milestone Achievement Program grant to support the development of its innovative, imaging-based antimicrobial diagnostic technology. 

PhAST goes international, opening a branch in Zurich, Switzerland – July 2019

PhAST opened a branch in the heart of Europe – Zurich – where it will continue to grow its top notch artificial intelligence and machine learning team.

PhAST selected to participate in MassBIO’s MassCONNECT program– August 2018

PhAST was selected among only a handful of startups to receive extensive mentorship by some of the area’s best entrepreneurs through the MassCONNECT program.

PhAST opens its Headquarters in Cambridge (MA) – April 2018

PhAST opened its Headquarters at Nest.Bio Labs, a brand-new biotech incubator in the heart of one of the fastest growing biotech hubs – Cambridge (MA).